A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.

ABSTRACT:

Introduction

Capmatinib is approved for MET exon 14-altered NSCLC on the basis of activity in targeted therapy-naive patients. We conducted a phase 2 study to assess the efficacy of capmatinib in patients previously treated with a MET inhibitor.

Methods

Patients with advanced NSCLC harboring MET amplification or MET exon 14 skipping alterations received capmatinib 400 mg twice daily. The primary end point was the objective response rate. Secondary end points included progression-free survival, disease control rate (DCR), intracranial response rate, and overall survival. Circulating tumor DNA was analyzed to identify capmatinib resistance mechanisms.

Results

A total of 20 patients were enrolled between May 2016 and November 2019, including 15 patients with MET skipping

SUBMITTER: Dagogo-Jack I 

PROVIDER: S-EPMC8922989 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature